Melhem Solh

20PUBLICATIONS
157CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Aug 23, 2025
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Timothy E O'Connor, Chenyu Lin, Gregory W Roloff

|Aug 11, 2025
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis.

Jordan Gauthier, Kwang W Ahn, Jinalben Patel

|Jan 03, 2025
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.

Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki

|Oct 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.

Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar

|Jul 31, 2024
HLA evolutionary divergence (HED) informs the effect of HLA-B mismatch on outcomes after haploidentical transplantation.

Melhem Solh, Michael T Aubrey, Xu Zhang

|Mar 12, 2024
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.

Mark J Levis, Mehdi Hamadani, Brent Logan

Pageof 4

Frequent Collaborators

6 joint publications

Vijaya Raj Bhatt

6 joint publications

Paul Castillo

6 joint publications

Taiga Nishihori

6 joint publications

Daniel Weisdorf